Analysts’ Top Healthcare Picks: Biogen (BIIB), Pacira Pharmaceuticals (PCRX)

TipRanks BlogTipRanks BlogOctober 12, 2021

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIBResearch Report) and Pacira Pharmaceuticals (PCRXResearch Report) with bullish sentiments.

Biogen (BIIB)

In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Biogen, with a price target of $400.00. The company’s shares closed last Monday at $285.59.

According to TipRanks.com, Yee is a 4-star analyst with an average return of 7.0% and a 45.6% success rate. Yee covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Vertex Pharmaceuticals, and Allogene Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $404.16 average price target, implying a 42.0% upside from current levels. In a report issued on September 27, Leerink Partners also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Pacira Pharmaceuticals (PCRX)

Jefferies analyst David Steinberg maintained a Buy rating on Pacira Pharmaceuticals yesterday and set a price target of $85.00. The company’s shares closed last Monday at $50.76, close to its 52-week low of $45.05.

According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 8.8% and a 49.0% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Verrica Pharmaceuticals, and Bausch Health Companies.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $79.22, implying a 75.0% upside from current levels. In a report issued on October 1, Barclays also maintained a Buy rating on the stock with a $91.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BIIB:

Source: TipRanks Blog

Powered by WPeMatico


Newsletter

 Sign up now to receive our Daily Newsletters, straight to your inbox.